Skip to main content
Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc. — Investor Relations & Filings

Ticker · NAUT ISIN · US63909J1088 US Professional, scientific and technical activities
Open in API
Filings indexed 299 across all filing types
Latest filing 2021-02-05 Major Shareholding Noti…
Country US United States of America
Listing US NAUT

About Nautilus Biotechnology, Inc.

https://www.nautilus.bio/

Nautilus Biotechnology, Inc. is a life sciences company developing a platform to revolutionize proteome analysis. The company's Proteome Analysis Platform is designed to quantify proteins at the single-molecule level, leveraging a proprietary method called Iterative Mapping. This technology aims to provide high-resolution views of billions of individual protein molecules and their modifications (proteoforms). The platform is being developed with two key modalities: broadscale proteomic analysis for comprehensive proteome exploration and targeted proteoform analysis for in-depth examination of protein variants. The intended applications include accelerating drug target identification, discovering more effective biomarkers, and enabling foundational biological research by making advanced proteomics more accessible to the scientific community.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2021
Major Shareholding Notification
2021-02-05 English
10-Q
Interim / Quarterly Report Q3 2020
2020-11-13 English
10-Q
Interim / Quarterly Report Q2 2020
2020-09-18 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 11, 2020. It reports the consummation of an initial public offering (IPO) and a private placement, including details about the offering proceeds and trust account arrangements. It also references an audited balance sheet as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The document is primarily an announcement of a material definitive agreement related to financing activities (IPO and private placement). Given the content focuses on capital raising and financing updates, the appropriate classification is Capital/Financing Update (CAP). The document length is just over 5,000 characters, so it is not a brief announcement but a substantive filing about financing events. Therefore, the best fit is CAP with high confidence.
2020-08-17 English
SC 13G
Major Shareholding Notification
2020-08-13 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about the consummation of an IPO, entry into material definitive agreements related to the IPO, private placement of shares, amendments to the company's memorandum and articles of association, and exhibits filed with the report. There are no financial statements or detailed financial performance data presented, but rather disclosures about corporate actions and agreements. This fits the definition of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit into more specific categories like Annual Report or Earnings Release. The document length is 8515 characters, which is substantial but the content is clearly a current report filing (8-K) rather than a full financial report or presentation.
2020-08-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.